Apimeds Pharmaceuticals Us, INC 10-Q quarterly reports
Quarterly reports, with unaudited financial statements and management’s discussion of the quarter just ended.
AMEX
Apimeds Pharmaceuticals US, Inc. reported a significantly wider net loss in Q3 2025 as it ramped up research and development activities following its $11.9 million IPO, despite ongoing internal control weaknesses.
AMEX
Apimeds Pharmaceuticals US, Inc. reported significantly increased net losses for Q2 2025 despite completing its initial public offering, alongside disclosing material weaknesses in internal financial controls.
AMEX
Apimeds Pharmaceuticals US, Inc. reports a net loss for Q1 2025, but highlights the completion of its IPO and subsequent conversion of related party debt.